1. Home
  2. WERN vs ALVO Comparison

WERN vs ALVO Comparison

Compare WERN & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Werner Enterprises Inc.

WERN

Werner Enterprises Inc.

SELL

Current Price

$27.60

Market Cap

2.0B

Sector

Industrials

ML Signal

SELL

Logo Alvotech

ALVO

Alvotech

SELL

Current Price

$4.29

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
WERN
ALVO
Founded
1956
2013
Country
United States
Luxembourg
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
WERN
ALVO
Price
$27.60
$4.29
Analyst Decision
Hold
Buy
Analyst Count
16
7
Target Price
★ $36.67
$7.50
AVG Volume (30 Days)
★ 984.6K
904.9K
Earning Date
10-27-2026
11-11-2026
Dividend Yield
★ 1.98%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.14
N/A
Revenue
★ $2,974,396,000.00
N/A
Revenue This Year
$22.96
$10.60
Revenue Next Year
$8.31
$22.47
P/E Ratio
$201.75
★ $18.20
Revenue Growth
N/A
★ N/A
52 Week Low
$23.06
$2.94
52 Week High
$47.49
$6.53

Technical Indicators

Market Signals
Indicator
WERN
ALVO
Relative Strength Index (RSI) 38.18 39.19
Support Level $26.85 $3.10
Resistance Level $29.68 $4.59
Average True Range (ATR) 0.99 0.29
MACD 0.22 -0.02
Stochastic Oscillator 25.00 16.48

Price Performance

Historical Comparison
WERN
ALVO

About WERN Werner Enterprises Inc.

Werner Enterprises Inc is a transportation and logistics company engaged in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.

About ALVO Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

Share on Social Networks: